8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2022

Humacyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39532	85-1763759
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

2525 East North Carolina Highway 54
Durham,	NC	27713
(Address of principal executive offices)		(Zip code)

(919) 313-9633

(Registrant’s telephone number, including area code)

Not Applicable 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	HUMA	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50	HUMAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 15, 2022, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed C. Bruce Green to the Board. General Green will serve as a Class I director and will be subject to election at the Company’s 2025 annual meeting of stockholders.

General Green has served as Director and Chief Medical Officer of Deloitte Federal Consulting since October 2013. From September 2012 through September 2013, General Green served as Senior Partner at Martin, Blanck & Associates, a consulting firm focused on the federal health sector. General Green served as the 20th Surgeon General of the U.S. Air Force from August 2009 through July 2012, during which time he oversaw all U.S. Air Force Medical Service activities, including a staff of over 42,800 people assigned to 75 medical facilities worldwide. Prior to serving as Surgeon General, General Green served as Assistant Surgeon General for Health Care Operations from July 2005 to August 2006 and Deputy Surgeon General of the U.S. Air Force from August 2006 to August 2009. General Green was commissioned through the Health Professions Scholarship Program and entered active duty with the U.S. Air Force in 1978, after completing his M.D. at the Medical College of Wisconsin. General Green completed residency training in family practice at Eglin Regional Hospital, Eglin Air Force Base, Florida, and in aerospace medicine at Brooks Air Force Base, Texas. General Green received his B.S. from the University of Wisconsin–Parkside and his M.P.H. from the Harvard School of Public Health. General Green retired from the U.S. Air Force in July 2012 with the rank of Lieutenant General.

For his service on the Company’s Board, General Green will participate in the Company’s previously disclosed compensation program for non-employee directors, pursuant to which he will receive (i) a $50,000 annual cash retainer (prorated in 2022 for his partial year of service), (ii) as a newly appointed director, an option to purchase 13,000 shares of the Company’s common stock, and, (iii) when considered a continuing director, an option to purchase 8,500 shares of the Company’s common stock annually.

There is no arrangement between General Green and any person pursuant to which he was selected as director. General Green has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

Item 7.01.  Regulation FD Disclosure.

On September 20, 2022, the Company issued a press release regarding General Green’s appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press release, dated September 20, 2022.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HUMACYTE, INC.
Date: September 20, 2022	By:	/s/ Dale A. Sander
		Name:	Dale A. Sander
		Title:	Chief Financial Officer, Chief Corporate Development Officer and Treasurer

2

EX-99.1

Exhibit 99.1

Humacyte Expands Board of Directors and Leadership Team with New Appointments

Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors

Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer

DURHAM, N.C., -- Sept. 20, 2022 -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, today announced the appointments of two distinguished healthcare professionals to the Company’s Board of Directors and leadership team. Lt. General Bruce Green, M.D., USAF-ret., former Surgeon General of the U.S. Air Force, joins as a member of the Board of Directors. In addition, pharma industry veteran Yang (Cindy) Cao, Ph.D. joins as the Company’s Chief Regulatory Officer. Current Chief Regulatory Officer, Bill Tente, will remain with Humacyte as an Executive Advisor, partnering on key regulatory initiatives for the organization with Dr. Cao and team.

“Bruce and Cindy are each accomplished medical and industry professionals with significant and complementary experience in public health, drug, and biotechnology development, as well as deep relationships with the governing authorities in their respective fields,” said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. “We are delighted to welcome them to the Humacyte leadership team, and look forward to their guidance as we advance our Human Acellular VesselsTM (HAV™) toward regulatory approval.”

General Green said, “With its off-the-shelf availability and resistance to infection, Humacyte’s HAV technology has enormous potential to aid in the care of vascular trauma, particularly in combat and natural disaster scenarios. This potential is evidenced by the recent case studies from Humacyte’s humanitarian relief effort where war victims have been treated at multiple front-line Ukrainian hospitals. I am honored to join the Humacyte Board and look forward to working with the leadership team to help bring this important advancement to market.”

Dr. Cao said, “Humacyte’s platform for implantable bioengineered human tissues could potentially lead to first in class regenerative medicine, with compelling applications in vascular trauma repair, arteriovenous access for hemodialysis and peripheral arterial disease. I am very excited to join the talented Humacyte team, and eager to begin working toward regulatory interactions and market authorization submissions of this critical product candidate to benefit the patients in need.”

Lt. General Green was commissioned through the Health Professions Scholarship Program and entered active duty in 1978 after earning his Doctorate of Medicine at the Medical College of Wisconsin in Milwaukee. He completed residency training in family practice at Eglin Regional Hospital, Eglin AFB, Fla., in 1981, and in aerospace medicine at Brooks AFB, Texas, in 1989. He is board certified in aerospace medicine. An expert in disaster relief operations, General Green planned and led humanitarian relief efforts in the Philippines after the Baguio earthquake in 1990 and in support of Operation Fiery Vigil following the 1991 eruption of Mount Pinatubo. General Green has served as commander of three hospitals and the Wilford Hall Medical Center. As command surgeon for three major commands, he planned joint medical response for operations Desert Thunder and Desert Fox, and oversaw aeromedical evacuation for operations Enduring Freedom and Iraqi Freedom. General Green served as Assistant Surgeon General for Health Care Operations and Deputy Surgeon General, and was appointed Air Force Surgeon General in 2009. General Green earned a B.S. in chemistry at the University of Wisconsin-Parkside and an M.D. at the Medical College of Wisconsin. General Green is also a graduate of the Air Command and Staff College, and earned a master’s degree in public health from Harvard University.

Dr. Cao brings over twenty years of drug discovery and development experience in pharmaceutical and biotech companies, including Bristol-Myer Squibb, Novartis, Novo Nordisk and Sanofi. Prior to joining Humacyte, Dr. Cao served as Senior Vice President and Head of Regulatory Affairs and Quality Assurance at Ascentage Pharma. Dr. Cao has also served in global and US executive leadership roles in Regulatory Affairs at pharmaceutical and biotech companies, and has functioned as an Executive Leadership Team member in multiple previous positions. Dr. Cao has extensive expertise in global and US regulatory strategy and policy on biologics, small molecules, and devices, and has provided guidance to development teams in various therapeutic areas including oncology, immunology, metabolic disorders, hematology and cardiovascular diseases. Before her industry roles, Dr. Cao was an Assistant Professor at the Huntsman Cancer Institute,

conducting basic research in oncology and inflammation. Dr. Cao holds a B.S. in genetics from Fudan University in Shanghai China, a Ph. D. in biomedical sciences from University of New Mexico, and completed an NIH-sponsored post-doctoral fellowship at the University of Utah.

About HAV

Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement – it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue. The HAV is currently being evaluated in two Phase 3 trials in arteriovenous access and a Phase 2/3 trial for vascular trauma, and has been used in nearly 500 patient implantations. Humacyte’s 6mm HAV for AV access for performing hemodialysis was the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), and has also received FDA Fast Track designation. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:

Joyce Allaire

LifeSci Advisors LLC

+1-617-435-6602

jallaire@lifesciadvisors.com

investors@humacyte.com

Humacyte Media Contact:

Elizabeth Miller, M.D.

LifeSci Communications LLC

+1-646-791-9705

emiller@lifescicomms.com

XML

Cover Page	Sep. 15, 2022
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Sep. 15, 2022
Entity Registrant Name	Humacyte, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-39532
Entity Tax Identification Number	85-1763759
Entity Address, Address Line One	2525 East North Carolina Highway 54
Entity Address, City or Town	Durham,
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27713
City Area Code	919
Local Phone Number	313-9633
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001818382
Amendment Flag	false
Common Stock, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	HUMA
Security Exchange Name	NASDAQ
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
Entity Information [Line Items]
Title of 12(b) Security	Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
Trading Symbol	HUMAW
Security Exchange Name	NASDAQ